Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01

Article Tools

• Email

  Thank you for your interest in spreading the word about Science Translational Medicine.

  NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

  Your Email

  Your Name

  Send To

  Enter multiple addresses on separate lines or separate them with commas.

  You are going to email the following Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01

  Message Subject (Your Name) has forwarded a page to you from Science Translational Medicine

  Message Body (Your Name) thought you would like to see this page from the Science Translational Medicine web site.

  Your Personal Message

  CAPTCHA

  This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

  Send Message
• Download Powerpoint
• Print
• Alerts

  Please log in to add an alert for this article.

  Log In with your AAAS ID

  Sign In to Email Alerts with your Email Address

  Email

  Log in
• Citation tools

  Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01

  By Guillem Pascual-Pasto, Miriam Bazan-Peregrino, Nagore G. Olaciregui, Camilo A. Restrepo-Perdomo, Ana Mato-Berciano, Daniela Ottaviani, Klaus Weber, Genoveva Correa, Sonia Paco, Monica Vila-Ubach, Maria Cuadrado-Vilanova, Helena Castillo-Ecija, Gaia Botteri, Laura Garcia-Gerique, Helena Moreno-Gilabert, Marta Gimenez-Alejandre, Patricia Alonso-Lopez, Marti Farrera-Sal, Silvia Torres-Manjon, Dolores Ramos-Lozano, Rafael Moreno, Isabelle Aerts, François Doz, Nathalie Cassoux, Elodie Chapeaublanc, Montserrat Torrebadell, Monica Roldan, Andrés König, Mariona Suñol, Joana Claverol, Cinzia Lavarino, Torres Carmen de, Ligia Fu, François Radvanyi, Francis L. Munier, Jaume Catalá-Mora, Jaume Mora, Ramón Alemany, Manel Cascalló, Guillermo L. Chantada, Angel M. Carcaboso

  Science Translational Medicine23 Jan 2019

  An oncolytic adenovirus shows antitumor efficacy in patient-derived models of intraocular retinoblastoma and appears safe for human use.

  • Supplementary Materials

  Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
• Share

  Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01

  By Guillem Pascual-Pasto, Miriam Bazan-Peregrino, Nagore G. Olaciregui, Camilo A. Restrepo-Perdomo, Ana Mato-Berciano, Daniela Ottaviani, Klaus Weber, Genoveva Correa, Sonia Paco, Monica Vila-Ubach, Maria Cuadrado-Vilanova, Helena Castillo-Ecija, Gaia Botteri, Laura Garcia-Gerique, Helena Moreno-Gilabert, Marta Gimenez-Alejandre, Patricia Alonso-Lopez, Marti Farrera-Sal, Silvia Torres-Manjon, Dolores Ramos-Lozano, Rafael Moreno, Isabelle Aerts, François Doz, Nathalie Cassoux, Elodie Chapeaublanc, Montserrat Torrebadell, Monica Roldan, Andrés König, Mariona Suñol, Joana Claverol, Cinzia Lavarino, Torres Carmen de, Ligia Fu, François Radvanyi, Francis L. Munier, Jaume Catalá-Mora, Jaume Mora, Ramón Alemany, Manel Cascalló, Guillermo L. Chantada, Angel M. Carcaboso

  Science Translational Medicine23 Jan 2019

  An oncolytic adenovirus shows antitumor efficacy in patient-derived models of intraocular retinoblastoma and appears safe for human use.

  • Supplementary Materials

  Share This Article: Copy